Effects of Metformin on Mitochondrial Function of Leukocytes from Polycystic Ovary Syndrome Patients with Insulin Resistance
Overview
Authors
Affiliations
Objective: Oxidative stress and mitochondrial dysfunction are implicated in polycystic ovary syndrome (PCOS). The present study assesses the effect of metformin treatment on mitochondrial function in polymorphonuclear cells from PCOS subjects. Additionally, we evaluate endocrine parameters and levels of interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα).
Design And Methods: Our study population was comprised of 35 women of reproductive age diagnosed with PCOS and treated with metformin for 12 weeks, and their corresponding controls (n=41), adjusted by age and BMI. We evaluated the alteration of endocrinological and anthropometrical parameters and androgen levels. Mitochondrial O2 consumption (using a Clark-type O2 electrode), membrane potential, mitochondrial mass, and levels of reactive oxygen species (ROS) and glutathione (GSH) (by means of fluorescence microscopy) were assessed in poymorphonuclear cells. H2O2 was evaluated with the Amplex Red(R) H2O2/Peroxidase Assay kit. IL6 and TNFα were measured using the Luminex 200 flow analyser system.
Results: Metformin had beneficial effects on patients by increasing mitochondrial O2 consumption, membrane potential, mitochondrial mass and glutathione levels, and by decreasing levels of reactive oxygen species and H2O2. In addition, metformin reduced glucose, follicle-stimulating hormone, IL6 and TNFα levels and increased dehydroepiandrosterone sulfate levels. HOMA-IR and mitochondrial function biomarkers positively correlated with ROS production (r=0.486, P=0.025), GSH content (r=0.710, P=0.049) and H2O2 (r=0.837, P=0.010), and negatively correlated with membrane potential (r=-0.829, P=0.011) at baseline. These differences disappeared after metformin treatment.
Conclusions: Our results demonstrate the beneficial effects of metformin treatment on mitochondrial function in leukocytes of PCOS patients.
Metformin and the Liver: Unlocking the Full Therapeutic Potential.
Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, DAvino M Metabolites. 2024; 14(4).
PMID: 38668314 PMC: 11052067. DOI: 10.3390/metabo14040186.
Mujammami M, Aleidi S, Buzatto A, Alshahrani A, AlMalki R, Benabdelkamel H Pharmaceuticals (Basel). 2023; 16(12).
PMID: 38139843 PMC: 10747765. DOI: 10.3390/ph16121717.
Ponce-Lopez T, Gonzalez Alvarez Tostado J, Dias F, Montiel Maltez K Biomolecules. 2023; 13(9).
PMID: 37759689 PMC: 10526195. DOI: 10.3390/biom13091289.
The interplay between androgens and the immune response in polycystic ovary syndrome.
Shabbir S, Khurram E, Moorthi V, Eissa Y, Kamal M, Butler A J Transl Med. 2023; 21(1):259.
PMID: 37062827 PMC: 10105935. DOI: 10.1186/s12967-023-04116-4.
Seylan C, Tarhan C FEMS Yeast Res. 2023; 23.
PMID: 36941121 PMC: 10103822. DOI: 10.1093/femsyr/foad018.